hrcak mascot   Srce   HID

Stručni rad

Intravitreal Bevacizumab (Avastin) in Treatment of Neovascular Age-related Macular Degeneration

Ratimir Lazić
Nikica Gabrić
Iva Dekaris
Borna Šarić
Morena Gavrić

Puni tekst: engleski, pdf (162 KB) str. 315-319 preuzimanja: 279* citiraj
APA 6th Edition
Lazić, R., Gabrić, N., Dekaris, I., Šarić, B. i Gavrić, M. (2007). Intravitreal Bevacizumab (Avastin) in Treatment of Neovascular Age-related Macular Degeneration. Collegium antropologicum, 31 - Supplement 1 (1), 315-319. Preuzeto s https://hrcak.srce.hr/27429
MLA 8th Edition
Lazić, Ratimir, et al. "Intravitreal Bevacizumab (Avastin) in Treatment of Neovascular Age-related Macular Degeneration." Collegium antropologicum, vol. 31 - Supplement 1, br. 1, 2007, str. 315-319. https://hrcak.srce.hr/27429. Citirano 20.10.2019.
Chicago 17th Edition
Lazić, Ratimir, Nikica Gabrić, Iva Dekaris, Borna Šarić i Morena Gavrić. "Intravitreal Bevacizumab (Avastin) in Treatment of Neovascular Age-related Macular Degeneration." Collegium antropologicum 31 - Supplement 1, br. 1 (2007): 315-319. https://hrcak.srce.hr/27429
Harvard
Lazić, R., et al. (2007). 'Intravitreal Bevacizumab (Avastin) in Treatment of Neovascular Age-related Macular Degeneration', Collegium antropologicum, 31 - Supplement 1(1), str. 315-319. Preuzeto s: https://hrcak.srce.hr/27429 (Datum pristupa: 20.10.2019.)
Vancouver
Lazić R, Gabrić N, Dekaris I, Šarić B, Gavrić M. Intravitreal Bevacizumab (Avastin) in Treatment of Neovascular Age-related Macular Degeneration. Collegium antropologicum [Internet]. 2007 [pristupljeno 20.10.2019.];31 - Supplement 1(1):315-319. Dostupno na: https://hrcak.srce.hr/27429
IEEE
R. Lazić, N. Gabrić, I. Dekaris, B. Šarić i M. Gavrić, "Intravitreal Bevacizumab (Avastin) in Treatment of Neovascular Age-related Macular Degeneration", Collegium antropologicum, vol.31 - Supplement 1, br. 1, str. 315-319, 2007. [Online]. Dostupno na: https://hrcak.srce.hr/27429. [Citirano: 20.10.2019.]

Sažetak
To evaluate the efficacy and safety of intravitreal bevacizumab in treatment of minimally classic and occult choroidal
neovascularization secondary to age-related macular disease 48 eyes of 48 patients (mean age of 74.8) included in this
prospective, noncomparative, interventional case series. Median follow-up was 18 weeks (6–24). Intravitreal bevacizumab
injection of 0.05 mL (1.25 mg) was administered at baseline and in 6 week intervals until leakage resolved, and repeated
in case of leakage recurrence. Visual acuity (VA) improved in the majority of patients (mean baseline VA=1.078
log MAR) by mean increase of 1.32 lines (last follow-up) (p=0.001). Central foveal thickness and total macular volume
decreased by 51 μm (p=0.01) and 0.84 mm3 (p<0.0001) respectively. No serious complications were observed. As initial
therapy, intravitreal bevacizumab appears to be safe and effective. A significant functional and anatomical improvement
was noted in majority of patients and maintained during follow-up.

Ključne riječi
bevacizumab; ranibizumab; pegaptanib

Hrčak ID: 27429

URI
https://hrcak.srce.hr/27429

Posjeta: 446 *